Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared an article by David A. Braun, et al. on X:
“A new era has just started in the treatment of kidney cancer!
This masterpiece study put novel insights on RCC treatment!
A Phase I trial of a personalized cancer vaccine in high-risk RCC shows no recurrences in 9 patients, strong T-cell responses against driver mutations (VHL, PBRM1, BAP1, etc.), and durable immune activation.”‘
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.
Authors: David A. Braun, et al.
